Prime Therapeutics
Pharmacy Benefit Management
Based in MN
AI Overview
With $828K in lobbying spend across 29 quarterly filings, Prime Therapeutics is an active lobbying client. Their lobbying covers 3 issue areas. Active from 2019 to 2025.
Spending Trend
View as table
| Year | Lobbying Spend |
|---|---|
| 2019 | $108K |
| 2020 | $120K |
| 2021 | $120K |
| 2022 | $120K |
| 2023 | $120K |
| 2024 | $120K |
| 2025 | $120K |
Issues Lobbied
Lobbying Firms
Lobbyists
Government Agencies Targeted
These are the government entities that Prime Therapeutics disclosed contacting in their lobbying filings.
What They Lobby About
These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Health Issues, Medicare/Medicaid, Budget/Appropriations
Issues relating to pharmaceutical value-based contracting and rebate transparency.
H.R 1781- Payment Commission Data Act of 2019; H.R. 965 & S. 340-The CREATES Act of 2019; issues relating to orphan drug exclusivity and value-based contracting; RIN 0936-AA08: Fraud and Abuse; Remova
General issues relating to PBM point of sale rebates, spread pricing and price transparency.
RIN 0936-AA08: Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in
Related Analysis
Related Investigations
Similar Clients
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.